WE ARE HIRING! - CLICK TO VIEW OPEN POSITIONS.

Presidio Medical

Building Tomorrow's Neuromodulation Therapies

We are a clinical-stage, privately held medical technology company developing a transformational neuromodulation platform to treat diseases of undesired neural activity.

Scientific Publication

Science Translational Medicine logo

Neuromodulation using ultra low frequency current waveform reversibly blocks axonal conduction and chronic pain

Authors: Martyn G. Jones, Evan Rogers, James P. Harris, Andrew Sullivan, D. Michael Ackermann, Marc Russo, Scott F. Lempka, and Stephen B. McMahon

Science Translational Medicine
August 25, 2021

Read Publication

KEY TAKEAWAYS:

  • Novel Ultra Low Frequency (ULF™) neuromodulation inhibits pain signals in pre-clinical animal models, computational models, and in a clinical trial
  • The mechanism of ULF™ neuromodulation is unique, enabling controlled and reversible inhibition of pain neurons through sodium channel inactivation. This mechanism of action is different than existing SCS technologies, which work by activating neurons
  • In a clinical trial, patients experienced a dramatic decrease in back pain with ULF™ neuromodulation therapy:
    • 95% of patients were responders (≥50% pain relief)
    • 90% of patients were profound responders (≥80% pain relief)
    • Patients experienced 90% reduction in back pain (starting VAS mean of 74.8 mm decreased to 7.6 mm at 15 days, p<0.001)
    • Patients did not experience paresthesia, or loss of sensation or function
  • ULF™ neuromodulation has a unique mechanism of action and is a promising, novel treatment for chronic pain

CAUTION: Investigational Device. Device for clinical investigation only.

Read Publication

Careers

We are a passionate team with diverse backgrounds in engineering, scientific research, patient care and commercializing disruptive products.

Big ideas are under construction, come build with us.

Learn More

Our initial indication is chronic pain. In the US alone approximately 50 million individuals suffer from chronic pain with treatment and economic costs of chronic pain totaling more than $560 billion each year1. Despite the mortality associated with opiate use, in 2018 there were over 168 million opiate prescriptions in the US according to the Centers for Disease Control (CDC), highlighting the need for better therapies.
Reference:
1 Gaskin DJ, Richard P. The Economic Costs of Pain in the United States. In: Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington (DC): National Academies Press (US); 2011.
50 MIL Suffer from chronic pain

The Presidio Team

Michael
Onuscheck

CEO & Chairman

Scott
Salys

Chief Research & Development and Operations Officer

Valerie
Cimmarusti

Senior Vice President, Regulatory, Quality & Clinical Ops

Katherine
Neuenfeldt

Senior Vice President, Commercial Strategies

Andrew
Sullivan

Chief Medical Officer

Michael
Onuscheck

CEO & Chairman

Scott
Salys

Chief Research & Development and Operations Officer

Valerie
Cimmarusti

Senior Vice President, Regulatory, Quality & Clinical Ops

Katherine
Neuenfeldt

Senior Vice President, Commercial Strategies

Andrew
Sullivan

Chief Medical Officer

Michael
Onuscheck

CEO & Chairman

Ben
Tsai

David
Neustaedter

Juan-Pablo
Mas

Michael
Ackermann

Kenneth
Wu

Michael
Onuscheck

CEO & Chairman

Ben
Tsai

David
Neustaedter

Juan-Pablo
Mas

Michael
Ackermann

Kenneth
Wu

Michael
Onuscheck

CEO & Chairman

Scott
Salys

Chief Research & Development and Operations Officer

Valerie
Cimmarusti

Senior Vice President, Regulatory, Quality & Clinical Ops

Katherine
Neuenfeldt

Senior Vice President, Commercial Strategies

Andrew
Sullivan

Chief Medical Officer

Michael
Onuscheck

CEO & Chairman

Ben
Tsai

David
Neustaedter

Juan-Pablo
Mas

Michael
Ackermann

Kenneth
Wu

Press Releases

Presidio Medical™ Announces $72M Equity Fundraising Led by Deerfield

Presidio Medical™ Announces Executive Appointment

Presidio MedicalTM Announces Publication of ULFTM Neuromodulation Research in Science Translational Medicine

Presidio Medical Announces Appointment of Chief Executive Officer

Presidio Medical Announces New Executive Appointment

Presidio Medical Announces $30 Million Financing Round Led By Invus Opportunities

Presidio Medical™ Announces $72M Equity Fundraising Led by Deerfield

Presidio Medical™ Announces Executive Appointment

Presidio MedicalTM Announces Publication of ULFTM Neuromodulation Research in Science Translational Medicine

Presidio Medical Announces Appointment of Chief Executive Officer

Presidio Medical Announces New Executive Appointment

Presidio Medical Announces $30 Million Financing Round Led By Invus Opportunities

Contact Us

For questions, comments, and inquiries, please use the form below.

Presidio Medical

Copyright © 2021 Presidio Medical, Inc.

LinkedIn

Michael Onuscheck

CEO & Chairman

Michael Onuscheck joined Presidio Medical in September 2021 as CEO and Chairman after serving more than two years as an independent member of Presidio’s board.   He made his move from Alcon Inc. where he served on the Executive Committee of Alcon and the President, Global Businesses & Innovation.  Prior to that role Michael led Alcon’s Surgical products business as President & General Manager helping to turn-around and then spin Alcon out of Novartis.

Michael joined Alcon in February 2015 from Boston Scientific where he held the position of President of EMEA and Russia.  Prior to this assignment, he served as Senior Vice President and President of Boston Scientific’s Neuromodulation Division for more than seven years and was a part of the acquired of Advanced Bionics management team. Michael’s career evolved through a variety of marketing and sales management positions at Medtronic Sofamor Danek and Pfizer.

Michael earned his degree in Business Administration and Psychology from Washington and Jefferson College in Washington, Pennsylvania. 

Scott Salys

Chief Research & Development and Operations Officer

Scott is the Chief Research & Development and Operations Officer at Presidio Medical. Scott has 25+ years experience in Class III active implantable devices and leading R&D, Operations, Supply Chain, Program Management, and Durable Medical Equipment (DME) organizations. Prior to joining Presidio Medical, he was the Divisional Vice President of R&D and Divisional Vice President of Operations at Abbott’s Heart Failure business, where he led the HF organization through rapid growth and expansion. Prior to Abbott’s acquisition of St. Jude Medical (SJM) in 2017, Mr. Salys spent over 16 years at SJM in R&D, Operations, and Supply Chain roles across various divisions and geographies. Scott received his B.S. in Bioengineering from Texas A&M University and holds 13 patents. 

Valerie Cimmarusti

Senior Vice President, Regulatory, Quality & Clinical Ops

Valerie is the Senior Vice President of Quality, Regulatory Affairs, and Clinical Operations at Presidio Medical. Valerie has 25+ years of Global Regulatory, Quality Assurance/Quality Control, Global Compliance and Clinical Operations experience. Valerie worked in Class III Implantable Medical Devices, Class II & I Devices, In-Vitro Diagnostics, Pharma & Biotech Industries. Valerie previously held roles at Boston Scientific, St. Jude Medical and Baxter Healthcare. Valerie received a B.S. in Microbiology with a minor in Chemistry from Cal Poly Pomona and obtained Regulatory Affairs Certification (RAC).

Katherine Neuenfeldt

Katherine Neuenfeldt

Senior Vice President, Commercial Strategies

Katherine is the Senior Vice President of Commercial Strategies at Presidio Medical. Katherine has 15+ years experience commercializing implantable medical devices. Prior to Presidio, she was the Vice President of Market Access at Nevro, and led the Market Access and Marketing functions as Nevro grew from a small, private company to a disruptive and established player. She also led multiple high-profile product launches while at Medtronic Endovascular and previously held roles at Johnson & Johnson, HealthTech, and Triage Consulting Group. Katherine received a B.A. in Human Biology from Stanford University, a M.S. in Epidemiology from the Stanford School of Medicine, and an M.B.A. from the Darden School of Business at the University of Virginia.

Andrew Sullivan

Andrew Sullivan

Chief Medical Officer

Andrew is Chief Medical Officer of Presidio Medical. Prior to Presidio, Andrew was in full-time practice as a board-certified anesthesiologist with Boulder Valley Anesthesiology as a full partner and member of the Executive Committee. During medical practice, Andrew was engaged in industry as an active consultant. He finished degrees in Biology and History, as well as his Medical Doctorate, from Indiana University. He completed his residency in Anesthesiology at the University of Colorado.

Michael Onuscheck

CEO & Chairman

Michael Onuscheck will join Presidio Medical in September 2021 as CEO and Chairman after serving more than two years as an independent member of Presidio’s board.   He made his move from Alcon Inc. where he served on the Executive Committee of Alcon and the President, Global Businesses & Innovation.  Prior to that role Michael led Alcon’s Surgical products business as President & General Manager helping to turn-around and then spin Alcon out of Novartis.

Michael joined Alcon in February 2015 from Boston Scientific where he held the position of President of EMEA and Russia.  Prior to this assignment, he served as Senior Vice President and President of Boston Scientific’s Neuromodulation Division for more than seven years and was a part of the acquired of Advanced Bionics management team. Michael’s career evolved through a variety of marketing and sales management positions at Medtronic Sofamor Danek and Pfizer.

Michael earned his degree in Business Administration and Psychology from Washington and Jefferson College in Washington, Pennsylvania. 

Ben Tsai

Ben Tsai

Ben is a partner at Invus Opportunities, a New York based investment firm that currently manages over $1.5 billion of capital. Ben joined Invus Opportunities in 2008 when the firm spun off from sister firm The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Ben leads investments by Invus Opportunities in growing private companies and works in close partnership with market-leading management teams and investors to create lasting value. Ben has served on the Board of Directors of numerous companies, both in the healthcare sector as well as in other industries. Prior to joining Invus Opportunities, Ben was a management consultant at the Monitor Group. Ben received a B.S. in business administration from the University of Southern California and an M.B.A. from Harvard Business School.

David Neustaedter

David Neustaedter, Ph.D., is a Venture Partner on the Medical Technologies team at Deerfield Management and joined the Firm in 2022. Prior to Deerfield, Dr. Neustaedter spent seven years as a Vice President, at Medtronic Ventures and, before Medtronic’s merger with Covidien, spent a further 7 years with Covidien including five years as a Vice President of Venture Capital. He has also held positions at Stryker Development, Leerink Swann/MEDACorp Strategy Consulting, Fletcher Spaght, and Braun Consulting. Dr. Neustaedter holds a B.Sc. in Cellular, Molecular, and Microbial Biology from University of Calgary, an M.B.A  from Yale University, and a Ph.D. in Molecular Biology from University of British Columbia.

Juan Pablo Mas

Juan-Pablo Mas

Juan-Pablo is a partner at Action Potential Venture Capital based in Palo Alto, CA, and invests in start-ups that are pioneering bioelectronic medicines. He is a Board member of various companies developing therapies that leverage “electricity as medicine,” a promising alternative to traditional drug therapies. He was previously a medical device investor at Lightstone Ventures and Morgenthaler Ventures. Prior to investing, Juan-Pablo led efforts across R&D and Strategy in Medtronic’s CardioVascular Division, and subsequently served on the CV Global Brand Strategy team at Eli Lilly. Juan-Pablo earned an MBA from Stanford Graduate School of Business, an M.S. in Electrical Engineering from Stanford, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on the Oversight Committee for Stanford’s Neuroscience Institute (Wu Tsai), the Advisory Board for UCSF’s Rosenman Institute, and is a founding Board Member of LatinxVC.

Michael Ackermann

Michael Ackermann

Michael Ackermann is co-founder and a board member of Presidio Medical. Michael is also co-founder and Chairman of Tarsus Pharmaceuticals (NASDAQ: TARS), and teaching faculty at the Stanford University Byers Center for Biodesign. Previous roles included co-founder and Chairman of Oyster Point Pharma (NASDAQ: OYST), Vice President, Neurostimulation for Allergan, plc and co-founder and CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University, M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University, and is a graduate of the Biodesign and Vision Research Fellowships at Stanford University. He has numerous patents and peer-reviewed publications.

Kenneth Wu

Kenneth Wu

Kenneth is a co-founder of Presidio Medical and previously served as President & CTO. Before Presidio, he was COO of Siris Medical, Inc an AI platform for enhancing radiation oncology treatment planning and outcomes. Prior to that, he was an R&D Program Manager at Spiracur Inc., a company focused on wound healing therapies, moving multiple products through early development to commercial release including FDA clearance and manufacturing implementation. Spiracur’s technology was acquired by Acelity L.P. He received his B.S.E. degree in mechanical and aerospace engineering from Princeton University, M.S. and Ph.D. degrees in mechanical engineering from Stanford University and is a graduate of the Stanford University Biodesign Fellowship.